Elsa Curtit

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Discordances in Estrogen Receptor Status, Progesterone Receptor Status, and HER2 Status Between Primary Breast Cancer and Metastasis

Elsa Curtit, Virginie Nerich, Laura Mansi et al. · The Oncologist · 2013 · 92 citations · Full text

Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report

Elsa Curtit, Antoine Thiery-Vuillemin, Thierry Nguyen et al. · Journal of Clinical Oncology · 2011 · 47 citations · Full text

Hepatology, Medicine, Histopathology +10

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity

Laurent Beziaud, Laura Mansi, Patrice Ravel et al. · Cancer Research · 2016 · 46 citations

A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects

Xavier Pivot, Elsa Curtit, Yoon Jung Lee et al. · Clinical Therapeutics · 2016 · 39 citations

Randomized Phase, Pharmacology, Pharmacotherapy +2